SYDNEY -- Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech and small to mid-size pharma companies to accelerate the development of advanced and novel therapeutics, today announced it was named a Fierce CRO Award winner by Fierce Biotech in the Clinical Trial Management and Global Operations categories.

“We’re grateful for this recognition, which is a direct result of our team’s effort and commitment to our mission,” said Novotech CEO Dr. John Moller. “It’s a reminder of what we can accomplish when we work together, and we look forward to continuing this momentum.”

The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations (CROs). These awards honor CROs that have demonstrated outstanding performance, innovation, and leadership in delivering high-quality research and development services. By recognizing the excellence of CROs, the awards aim to highlight the critical role they play in advancing life sciences research and improving patient outcomes.

“The Fierce CRO Awards recognize and celebrate the remarkable achievements of Contract Research Organizations in the life sciences industry,” said Rebecca Willumson, SVP and Publisher of Fierce Biotech and Fierce Pharma. “This inaugural program showcases an elite class working to advance research and development and further the industry as a whole.”

This is the inaugural year of the Fierce CRO Awards. Award winners were judged on: Innovation and Impact, Measurable Outcomes, Sustainability and Scalability, and Ethical and Regulatory Adherence.

Winners are featured in the Fierce CRO Report. Click here to read the report.